JP2023519247A - Ｆａｐ標的化放射性医薬品およびイメージング剤、ならびにそれらに関連する使用 - Google Patents

Ｆａｐ標的化放射性医薬品およびイメージング剤、ならびにそれらに関連する使用 Download PDF

Info

Publication number
JP2023519247A
JP2023519247A JP2022557768A JP2022557768A JP2023519247A JP 2023519247 A JP2023519247 A JP 2023519247A JP 2022557768 A JP2022557768 A JP 2022557768A JP 2022557768 A JP2022557768 A JP 2022557768A JP 2023519247 A JP2023519247 A JP 2023519247A
Authority
JP
Japan
Prior art keywords
compound
agent
fap
compound according
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557768A
Other languages
English (en)
Japanese (ja)
Inventor
ダブリュー バコフチン，ウィリアム
ライ，フン－セン
ウー，ウェンゲン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of JP2023519247A publication Critical patent/JP2023519247A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022557768A 2020-03-24 2021-03-24 Ｆａｐ標的化放射性医薬品およびイメージング剤、ならびにそれらに関連する使用 Pending JP2023519247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993874P 2020-03-24 2020-03-24
US62/993,874 2020-03-24
PCT/US2021/023862 WO2021195198A1 (en) 2020-03-24 2021-03-24 Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto

Publications (1)

Publication Number Publication Date
JP2023519247A true JP2023519247A (ja) 2023-05-10

Family

ID=77890585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557768A Pending JP2023519247A (ja) 2020-03-24 2021-03-24 Ｆａｐ標的化放射性医薬品およびイメージング剤、ならびにそれらに関連する使用

Country Status (15)

Country Link
US (2) US11707539B2 (ko)
EP (1) EP4126053A1 (ko)
JP (1) JP2023519247A (ko)
KR (1) KR20220158038A (ko)
CN (1) CN115697413A (ko)
AU (1) AU2021244541A1 (ko)
BR (1) BR112022019121A2 (ko)
CA (1) CA3171183A1 (ko)
CL (1) CL2022002603A1 (ko)
CO (1) CO2022014985A2 (ko)
IL (1) IL296658A (ko)
MX (1) MX2022011842A (ko)
PE (1) PE20230490A1 (ko)
TW (1) TW202202150A (ko)
WO (1) WO2021195198A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202202150A (zh) 2020-03-24 2022-01-16 美商杜夫特學院信託管理公司 靶向fap之放射性藥品及造影劑，與其相關用途
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
WO2023069711A1 (en) * 2021-10-22 2023-04-27 Trustees Of Tufts College Fap-targeted neutron capture agents, and uses and formulations related thereto
CN114149489B (zh) * 2021-11-18 2023-12-15 厦门大学 一种靶向tigit的放射性标记化合物及其制备方法和应用
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用
CN116650679A (zh) * 2023-04-14 2023-08-29 河北医科大学第四医院 一种靶向fgfr1的影像探针及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125227A2 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US7998997B2 (en) * 2005-07-05 2011-08-16 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
WO2010036814A1 (en) * 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
GB2538023A (en) * 2014-02-03 2016-11-02 Philochem Ag Targeted drug conjugates
CN116474108A (zh) * 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
CN112912731A (zh) * 2018-10-17 2021-06-04 普渡研究基金会 成纤维细胞活化蛋白(fap)靶向成像和纤维化治疗
TW202202150A (zh) 2020-03-24 2022-01-16 美商杜夫特學院信託管理公司 靶向fap之放射性藥品及造影劑，與其相關用途

Also Published As

Publication number Publication date
TW202202150A (zh) 2022-01-16
EP4126053A1 (en) 2023-02-08
PE20230490A1 (es) 2023-03-23
US11707539B2 (en) 2023-07-25
KR20220158038A (ko) 2022-11-29
CN115697413A (zh) 2023-02-03
CL2022002603A1 (es) 2023-05-26
AU2021244541A1 (en) 2022-10-13
CO2022014985A2 (es) 2022-12-30
CA3171183A1 (en) 2021-09-30
US20220370647A1 (en) 2022-11-24
IL296658A (en) 2022-11-01
BR112022019121A2 (pt) 2023-02-14
WO2021195198A1 (en) 2021-09-30
MX2022011842A (es) 2022-10-20
US20230330275A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US11707539B2 (en) FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
US20220211883A1 (en) Fap-activated radiotheranostics and uses related thereto
JP2021502368A (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用
US11730834B2 (en) Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
Meher et al. Prostate-specific membrane antigen targeted deep tumor penetration of polymer nanocarriers
Bandyopadhyay et al. Ligand-based active targeting strategies for cancer theranostics
US20240207292A1 (en) Boronic acid compounds, compositions and methods
JP2022501441A (ja) 癌を治療する方法
CN113166087A (zh) 屏蔽剂及其用途
CN112368024A (zh) 治疗癌症的方法
JP2024511054A (ja) ボロン酸化合物、組成物および方法
TW202340226A (zh) 碳酸酐酶ix配位體
WO2023209122A1 (en) Combination treatment of small-cell lung cancer
JP2009161477A (ja) 腫瘍イメージング剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240322